D
David Elashoff
Researcher at University of California, Los Angeles
Publications - 519
Citations - 28932
David Elashoff is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 70, co-authored 479 publications receiving 23935 citations. Previous affiliations of David Elashoff include City of Hope National Medical Center & Stanford University.
Papers
More filters
Journal ArticleDOI
Relation of Patent Foramen Ovale to Acute Mountain Sickness
Brian H. West,Rubine Gevorgyan Fleming,Bashar Al hemyari,Pooya Banankhah,Kenneth Meyer,Leslie H. Rozier,Linda S. Murphy,Alexandra Coluzzi,Joshua Rusheen,Preetham Kumar,David Elashoff,Jonathan M. Tobis +11 more
TL;DR: Clinicians should consider PFO a risk factor for acute mountain sickness in patients who plan to hike to high altitudes as hikers with a PFO had significantly higher risk of developing AMS relative to hikers without a P FO.
Journal ArticleDOI
Electronic Video Consent to Power Precision Health Research: A Pilot Cohort Study
Arash Naeim,Sarah M. Dry,David Elashoff,Zhuoer Xie,Antonia Petruse,Clara E. Magyar,Liliana Johansen,Gabriela Werre,Clara Lajonchere,Neil S. Wenger +9 more
TL;DR: The pilot demonstrated that the electronic video consent was well received by patients, with high scores for usefulness, ease, and trustworthiness even among patients that opted out of participation.
Journal ArticleDOI
Role of Clinical and Imaging Risk Factors in Predicting Breast Cancer Diagnosis Among BI-RADS 4 Cases.
William Hsu,Xinkai Zhou,Antonia Petruse,Ngan Chau,Stephanie Lee-Felker,Anne C. Hoyt,Neil S. Wenger,David Elashoff,Arash Naeim +8 more
TL;DR: While BI‐RADS assessment remains the strongest predictor of breast cancer, the inclusion of clinical risk factors such as age, breast density, presence of a lump, and number of risk triggers derived from guidelines improves the specificity of identifying individuals with imaging descriptors associated with BI‐ RADS 4A and 4B that are more likely to be diagnosed with breast cancer.
Journal ArticleDOI
Nanoscale Extracellular Vesicles Carry the Mechanobiology Signatures of Breast Cancer Cells
Michael LeClaire,James A. Wohlschlegel,Helena R. Chang,Madhuri Wadehra,Weibo Yu,Jianyu Rao,David Elashoff,James K. Gimzewski,Shivani Sharma +8 more
TL;DR: Breast cancer cells secrete abundant nanometer-sized vesicles and small extracellular vesicle cargos are known to have similar biomolecular signatures to their secreting parental breast cance...
Journal ArticleDOI
Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
R. Philipson,Tahmineh Romero,J.K. Wong,Bradley J. Stish,Robert T. Dess,Daniel E. Spratt,Avinash Pilar,Avinash Pilar,Chandana A. Reddy,Trude B. Wedde,Wolfgang Lilleby,Ryan Fiano,Gregory S. Merrick,Richard G. Stock,D. Jeffrey Demanes,Brian J. Moran,Michelle H. Braccioforte,Phuoc T. Tran,Santiago Martin,Rafael Martínez-Monge,Daniel J. Krauss,Eyad Abu-Isa,Luca F. Valle,Natalie Chong,Thomas M. Pisansky,C. Richard Choo,Danny Y. Song,Stephen Greco,Curtiland Deville,Todd McNutt,Theodore L. DeWeese,Ashley E. Ross,Jay P. Ciezki,Derya Tilki,R. Jeffrey Karnes,Eric A. Klein,Jeffrey J. Tosoian,Paul C. Boutros,Nicholas G. Nickols,Nicholas G. Nickols,Prashant Bhat,David Shabsovich,Jesus E. Juarez,Patrick A. Kupelian,Matthew Rettig,Matthew Rettig,Alejandro Berlin,Jonathan D. Tward,Brian J. Davis,Robert E. Reiter,Michael L. Steinberg,David Elashoff,Eric M. Horwitz,Rahul D. Tendulkar,Amar U. Kishan +54 more
TL;DR: In this article, the authors evaluated rates of distant metastases and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent high-risk prostate cancer (HRPCa) who previously received either external beam radiation therapy (EBRT, n = Â654, 67%) or EBRT+ Âbrachytherapy (eBRT Â+ÂBT, nÂ= Â324, 33%) across 15 institutions from 1997 to 2015.